1. Home
  2. FSBC vs CGEM Comparison

FSBC vs CGEM Comparison

Compare FSBC & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Five Star Bancorp

FSBC

Five Star Bancorp

HOLD

Current Price

$41.96

Market Cap

860.4M

Sector

Finance

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$13.77

Market Cap

904.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSBC
CGEM
Founded
2002
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
860.4M
904.7M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
FSBC
CGEM
Price
$41.96
$13.77
Analyst Decision
Buy
Strong Buy
Analyst Count
5
8
Target Price
$41.90
$30.13
AVG Volume (30 Days)
74.7K
881.8K
Earning Date
04-27-2026
05-11-2026
Dividend Yield
2.47%
N/A
EPS Growth
28.32
N/A
EPS
0.87
N/A
Revenue
N/A
N/A
Revenue This Year
$30.25
N/A
Revenue Next Year
$12.30
$5.20
P/E Ratio
$48.28
N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.26
$5.68
52 Week High
$42.26
$16.74

Technical Indicators

Market Signals
Indicator
FSBC
CGEM
Relative Strength Index (RSI) 60.54 42.75
Support Level $39.93 $12.41
Resistance Level N/A $16.21
Average True Range (ATR) 1.00 0.94
MACD 0.03 -0.16
Stochastic Oscillator 78.74 11.57

Price Performance

Historical Comparison
FSBC
CGEM

About FSBC Five Star Bancorp

Five Star Bancorp is a bank holding company that operates in California through its subsidiary, a state-chartered non-member bank. The company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans, and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment: Banking.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: